From the whole genome to the right drug.
INNOONE turns whole-genome sequencing data into accurate diagnosis, optimal drug recommendation and new drug targets — one end-to-end AI platform, built by cancer-genomics researchers in South Korea.
WGS · RNA · proteomics · clinical records, pseudonymised at source.
Germline and somatic variants, structural changes, cancer & disease risk scores.
Matched existing therapies, dose guidance and structure-based drug-target discovery.
Two divisions, one End-to-End AI
Most tools stop at a report. INNOONE connects interpretation to therapy and to discovery, so the same genome that diagnoses a patient also points to the drug — and to the next drug.
Whole-genome interpretation for clinics and biobanks
Analysis, interpretation and reporting of WGS and multi-omics data — for cancer patients today and for the healthy population's lifetime risk.
- INNOVANOME — multi-omics variant analysis: coding & non-coding, structural and copy-number changes, clonal evolution.
- INNOPORTAL — clinical data browser and reporting for care teams.
- INOME — personal genome platform: pharmacogenomic drug-safety card, hereditary risk, lifetime re-analysis.
- INODE — pseudonymisation and federated analysis: the genome never leaves the institution.
From a patient's mutations to the right molecule
AI-predicted protein structures and structure-similarity search turn genomic findings into treatment options and validated targets.
- INNOVA — drug repurposing and optimal-therapy recommendation by protein-structure similarity, including dose and combination support.
- INNODAC — antigen / antibody candidate discovery and cleavage-aware target refinement for antibody-drug conjugates (ADC).
- Validated on 13 metalloprotease substrates · published in Scientific Reports (Nature Portfolio), 2026.
One blood draw, a lifetime of safer prescriptions
Health systems already pay for single-gene answers — DPYD testing before 5-FU chemotherapy is standard in Europe. We deliver the same certainty from the whole genome, for every actionable gene at once.
Drug-safety card
Full pharmacogenomic panel (DPYD, UGT1A1, NUDT15, HLA-B*58:01, CYP2C19, VKORC1 …) — definitive, immediate.
Silent hereditary risks
Familial hypercholesterolaemia, hereditary cancers (BRCA and beyond) — definitive, life-saving.
Family card
Carrier status passed to the next generation — definitive, inherited.
Risk scores & re-analysis
Cancer, dementia and metabolic onset risk scores, re-analysed every year as evidence grows.
Global by design
Data stays where it is. Only the analysis travels. Our pseudonymisation and federated-analysis module (INODE) lets hospitals and biobanks in Europe, the Americas and Asia use INNOONE without exporting a single genome.
Selected for the Gyeonggi Province AI Cluster Global Programme (Europe)
One of up to ten Korean AI companies selected to meet Nordic and European investors, hospitals and pharma. Read more ↗
Eight months since founding, proven by execution
Not an early-stage idea but an AI-native company inheriting twenty years of national genome research.
Incorporated in Seongnam · in-house GPU cluster (H100 · A100 · RTX 6000)
Two core patents filed · clinical PoC at four sites
INNODAC paper published in Scientific Reports
Gyeonggi Province AI Membership company
Slush 2026, Helsinki — European PoC and investor talks
Company
INNOONE Inc. was founded in 2026 in Seongnam, South Korea, by cancer-genomics researchers and biotech operators whose work spans national genome programmes, Big-5 hospital validation and a KOSDAQ technology listing.
National genome programmes
Founders have led genome analysis for Korea's national precision-medicine and bio-big-data initiatives and contribute to the ICGC-ARGO consortium.
Validated where it matters
AI clinical-decision-support and data portals built with the National Cancer Center and leading university hospitals.
Operators, not only scientists
Leadership with venture-finance and public-listing experience, and a self-sustaining domestic health-check business funding global expansion.
Let's talk
Clinical or biobank partners, pharma collaborators and investors — we reply within two business days.